<![CDATA[Pengobatan pada kanker payudara dengan kemoterapi kombinasi Fluorouracil, Doxorubicin, dan Cyclofosfamide (FAC) menimbulkan perbedaan kualitas hidup pasien yang penting untuk diketahui karena dapat menunjang keefektifan pengobatan. Tujuan penelitian ini adalah untuk mengukur perbedaan dan mengetahui dimensi yang memengaruhi kualitas hidup pasien kanker payudara dari setiap siklus kemoterapi di RS Hasan Sadikin Bandung. Jenis penelitian ini adalah observasional analitik dengan pedekatan potong lintang. Sebanyak 200 pasien kanker payudara dipilih secara purposive dan dipisahkan berdasarkan siklus terapi. Penilaian kualitas hidup dilakukan secara multidimensional menggunakan instrumen EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) C30 dan BR23. Analisis data dihitung menggunakan uji t independen dan regresi linier berganda. Hasil penelitian menunjukkan terdapat perbedaan kualitas hidup yang sangat signifikan antara skala fungsi QLQ-C30 baseline dengan terapi ke-5, skala gejala QLQ-C30 baseline dengan terapi ke-5, skala fungsi QLQ-BR23 baseline dengan terapi ke-1, 2, 3, 4, dan 5, skala gejala QLQ-BR23 baseline dengan terapi ke-4, kemudian perbedaan signifikan antara skala gejala QLQ-BR23 baseline denganterapi ke-1, 3, dan 5. Dimensi yang berpengaruh signifikan terhadap kualitas hidup adalah fungsi sosial, mual dan muntah, gangguan pernapasan, gangguan tidur, dan kesulitan keuangan.Kata kunci: BR23, EORTC QLQ C30, kanker payudara, kualitas hidupQuality of Life Patients with Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, and CyclofosfamideTreatment of breast cancer with combination chemotherapy Florouracil, doxorubicin, and Cyclofosfamide (FAC) lead to differences in the quality of life of patients is important to know because it can support the effectiveness of patient treatment. The aim of the study was to measure the difference and know the dimensions that affect the quality of life of breast cancer patients from each cycle of chemotherapy in Hasan Sadikin Hospital. This research is an observational analytic cross sectional approach. A sample of 200 breast cancer patients who were selected purposively and separated based on cycles of therapy. Assessment of quality of life of patients is done using a multidimensional instrument EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) C30 and BR23. Data analysis was calculated using independent t test and linear regression. The results showed that there are differences in quality of life is very significant between QLQ-C30 functioning scale baseline with treatment 5, the QLQ-C30 symptom scale baseline therapy 5th, QLQ-BR23 function scale baseline with therapy 1st, 2nd, 3rd, 4th, and 5th, QLQ-BR23 symptoms scale baseline with therapy 4th, then a significant difference between scale symptoms of QLQ-BR23 baseline therapy with the 1st, 3rd, and 5th. Dimensions have a significant effect on quality of life is a social function, nausea and vomiting, dyspnea, sleep disorders and financial difficulties.Key words: BR23, breast cancer, EORTC QLQ C30, quality of life]]>
